Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bionik Laboratories Corp. (BNKL : OTC)
 
 • Company Description   
Bionik Laboratories Corp. is a medical device and robotics company which focuses in developing transformational technologies and solutions for individuals with neurological disorders. The company offers ARKE, a lower body exoskeleton for wheelchair bound individuals suffering from spinal cord injuries, strokes and other mobility disabilities to restore gait and walk again during the rehabilitation process. It also provides Cronos and the Apollo research programs. Chronos system is a patient queuing system for clinics and hospitals; Apollo is an above-the-knee prosthetic device. Bionik Laboratories Corp. is headquartered in Toronto, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: 1 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $0.00
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
80 COOLIDGE HILL ROAD
-
WATERTOWN,MA 02472
USA
ph: 617-926-4800
fax: -
rrusso@bioniklabs.com http://www.bioniklabs.com
 
 • General Corporate Information   
Officers
Rich Russo - Chief Executive Officer
Andre Auberton - Chairman of the Board
Dan Gonsalves - Chief Financial Officer and Executive Vice Preside
Michal Prywata - Director
Remi Gaston Dreyfus - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 09074A208
SIC: 3842
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 10.00 (0.01:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©